Vinflunine TartrateCAS# 1201898-17-0 |
- Docetaxel
Catalog No.:BCN5342
CAS No.:114977-28-5
- ABT-751 (E7010)
Catalog No.:BCC1085
CAS No.:141430-65-1
- Epothilone A
Catalog No.:BCC1091
CAS No.:152044-53-6
- Epothilone B (EPO906, Patupilone)
Catalog No.:BCC1092
CAS No.:152044-54-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1201898-17-0 | SDF | Download SDF |
PubChem ID | 53245637 | Appearance | Powder |
Formula | C49H60F2N4O14 | M.Wt | 967.02 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in DMSO > 10 mM | ||
Chemical Name | (2R,3R)-2,3-dihydroxybutanedioic acid;methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-4-[(12S,14R,16R)-16-(1,1-difluoroethyl)-12-methoxycarbonyl-1,10-diazatetracyclo[12.3.1.03,11.04,9]octadeca-3(11),4,6,8-tetraen-12-yl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate | ||
SMILES | CCC12C=CCN3C1C4(CC3)C(C(C2OC(=O)C)(C(=O)OC)O)N(C5=CC(=C(C=C45)C6(CC7CC(CN(C7)CC8=C6NC9=CC=CC=C89)C(C)(F)F)C(=O)OC)OC)C.C(C(C(=O)O)O)(C(=O)O)O | ||
Standard InChIKey | TXONSEMUKVZUON-SYVFVGEFSA-N | ||
Standard InChI | InChI=1S/C45H54F2N4O8.C4H6O6/c1-8-42-14-11-16-51-17-15-43(36(42)51)30-19-31(34(56-5)20-33(30)49(4)37(43)45(55,40(54)58-7)38(42)59-25(2)52)44(39(53)57-6)21-26-18-27(41(3,46)47)23-50(22-26)24-29-28-12-9-10-13-32(28)48-35(29)44;5-1(3(7)8)2(6)4(9)10/h9-14,19-20,26-27,36-38,48,55H,8,15-18,21-24H2,1-7H3;1-2,5-6H,(H,7,8)(H,9,10)/t26-,27-,36+,37-,38-,42-,43-,44+,45+;1-,2-/m11/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Vinflunine Tartrat is a new vinca alkaloid uniquely fluorinated with the properties of mitotic-arresting and tubulin-interacting activity.
Target: Microtubule/Tubulin
The major effects of Vinflunine on dynamic instability are a slowing of the microtubule growth rate, an increase in growth duration, and a reduction in shortening duration. The effects of Vinflunine on the readmilling rate is examined by following [3H]GTP incorporation into MAP-rich microtubules, and the IC50 is 0.42 μM [1]. Vinflunine induced mitotic accumulation with IC50 with 18.8 nM, which decreases the centromere dynamicity by 44% and increases the time centromeres spent ina paused state by 63% [2]. Treatment of Vinflunine induces a rapid change in endothelial cell shape: cells retracts and assumes a rounded morphology. Mean IC50 values are 9.9 × 10-5 M × 10-5 M for fibronectin and 5.0× 10-5 M × 10-5 M for type IV collagen. A short 4 hours exposure of endothelial cells to Vinflunine at 10-8 References: |
Vinflunine Tartrate Dilution Calculator
Vinflunine Tartrate Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.0341 mL | 5.1705 mL | 10.341 mL | 20.6821 mL | 25.8526 mL |
5 mM | 0.2068 mL | 1.0341 mL | 2.0682 mL | 4.1364 mL | 5.1705 mL |
10 mM | 0.1034 mL | 0.5171 mL | 1.0341 mL | 2.0682 mL | 2.5853 mL |
50 mM | 0.0207 mL | 0.1034 mL | 0.2068 mL | 0.4136 mL | 0.5171 mL |
100 mM | 0.0103 mL | 0.0517 mL | 0.1034 mL | 0.2068 mL | 0.2585 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Vinflunine is a new vinca alkaloid uniquely fluorinated with the properties of mitotic-arresting and tubulin-interacting activity. Phase 2/3.
- Crotaleschenine
Catalog No.:BCN2077
CAS No.:120154-95-2
- IPI-145 (INK1197)
Catalog No.:BCC1104
CAS No.:1201438-56-3
- Flavanthrin
Catalog No.:BCN3687
CAS No.:120090-80-4
- Fmoc-D-Arg(Mtr)-OH
Catalog No.:BCC3078
CAS No.:120075-24-3
- CRF (6-33)
Catalog No.:BCC5791
CAS No.:120066-38-8
- Shizukanolide F
Catalog No.:BCN6411
CAS No.:120061-96-3
- Meridinol
Catalog No.:BCN6087
CAS No.:120051-54-9
- Edgeworin
Catalog No.:BCN6561
CAS No.:120028-43-5
- VCH-916
Catalog No.:BCC2031
CAS No.:1200133-34-1
- Donepezil HCl
Catalog No.:BCC4569
CAS No.:120011-70-3
- Dichlorphenamide
Catalog No.:BCC3761
CAS No.:120-97-8
- 1,2-Benzenediol
Catalog No.:BCN6103
CAS No.:120-80-9
- MLN9708
Catalog No.:BCC2091
CAS No.:1201902-80-8
- TCS 2210
Catalog No.:BCC7798
CAS No.:1201916-31-5
- Cynoglossamine
Catalog No.:BCN1970
CAS No.:120193-39-7
- 3,4-Dihydroxycinnamamide
Catalog No.:BCN6090
CAS No.:1202-41-1
- Clopidogrel
Catalog No.:BCC2497
CAS No.:120202-66-6
- Clopidogrel Related Compound C
Catalog No.:BCN2689
CAS No.:120202-71-3
- NMS-P715
Catalog No.:BCC6373
CAS No.:1202055-34-2
- Tenidap
Catalog No.:BCC7419
CAS No.:120210-48-2
- 1beta-Hydroxyeuscaphic acid
Catalog No.:BCN3517
CAS No.:120211-98-5
- CGS 21680
Catalog No.:BCC1475
CAS No.:120225-54-9
- AVL-292
Catalog No.:BCC1385
CAS No.:1202757-89-8
- CNX-774
Catalog No.:BCC4394
CAS No.:1202759-32-7
[Characterization of vinflunine tartrate liposomes in vitro and in vivo].[Pubmed:22375428]
Yao Xue Xue Bao. 2011 Dec;46(12):1515-9.
Vinflunine Tartrate-loaded liposomes (VT-L) with two drug-to-lipid ratios were prepared by pH gradient method. Vesicle size and zeta potential were determined by the Zetasizer Nano ZS. Entrapment efficiency was evaluated by cation exchange resin centrifugalization method. The toxicity and tumor inhibition to nude mouse administrated by VT-L with different drug-to-lipid ratios were investigated and compared with the Vinflunine Tartrate injection (VT-I). The results showed that the mean particle size, zeta potential and entrapment efficiency of the VT-L with drug-to-lipid ratios of 1 : 5 and 1 : 10 were 124.6 nm and 128.3 nm, -25.3 mV and -22.8 mV, 94.46% and 97.31%, respectively. The VT-L with two different drug-to-lipid ratios has significantly higher anti-tumor effect to nude mouse transplanted human non-small cell lung carcinoma A549 and lower toxicity than VT-I. While there were no significant differences in anti-tumor effect and toxicity between VT-L with two different drug-to-lipid ratios.